Last reviewed · How we verify

heparin + clopidogrel + aspirin — Competitive Intelligence Brief

heparin + clopidogrel + aspirin (heparin + clopidogrel + aspirin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiplatelet and anticoagulant combination. Area: Cardiovascular.

marketed Antiplatelet and anticoagulant combination Thrombin, Factor Xa, Cyclooxygenase, P2Y12 receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

heparin + clopidogrel + aspirin (heparin + clopidogrel + aspirin) — Centre Hospitalier de PAU. This triple antiplatelet and anticoagulant combination inhibits blood clot formation through multiple pathways: heparin blocks thrombin and factor Xa, while clopidogrel and aspirin inhibit platelet aggregation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
heparin + clopidogrel + aspirin TARGET heparin + clopidogrel + aspirin Centre Hospitalier de PAU marketed Antiplatelet and anticoagulant combination Thrombin, Factor Xa, Cyclooxygenase, P2Y12 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiplatelet and anticoagulant combination class)

  1. Centre Hospitalier de PAU · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). heparin + clopidogrel + aspirin — Competitive Intelligence Brief. https://druglandscape.com/ci/heparin-clopidogrel-aspirin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: